054050 — Nong Woo Bio Co Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩125bn
- KR₩128bn
- KR₩136bn
- 81
- 71
- 19
- 61
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 17,253 | 20,996 | 15,457 | 24,131 | 34,445 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 46,774 | 47,456 | 48,326 | 52,134 | 50,330 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 159,701 | 170,253 | 179,398 | 201,066 | 201,720 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 82,258 | 79,644 | 80,116 | 75,202 | 68,475 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 289,864 | 301,692 | 311,049 | 327,393 | 323,809 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 52,265 | 59,384 | 61,469 | 72,910 | 61,795 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 59,034 | 65,570 | 67,414 | 77,950 | 66,442 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 230,831 | 236,121 | 243,634 | 249,442 | 257,366 |
Total Liabilities & Shareholders' Equity | 289,864 | 301,692 | 311,049 | 327,393 | 323,809 |
Total Common Shares Outstanding |